Hypereosinophilic Syndrome Clinical Trials

36 clinical trials for Hypereosinophilic Syndrome across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression — RECRUITING
• Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial — RECRUITING · PHASE3
• A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES) — RECRUITING · PHASE3
• Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents — RECRUITING · PHASE2
• Natural History of Hypereosinophilia and Hypereosinophilic Syndromes — RECRUITING
• Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders — RECRUITING · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DEPEMOKIMAB IN ADULTS WITH HYPEREOSINOPHILIC SYNDROME (HES) — RECRUITING
• An open-label extension study to study 100185, to evaluate long-term safety, efficacy and optimal dosing frequency of 750mg intravenous mepolizumab in subjects with hypereosinophilic syndrome. — COMPLETED · PHASE3
• A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-Week Phase III Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES) — TERMINATED · PHASE3
• A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) — ACTIVE_NOT_RECRUITING · PHASE3
• Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) — COMPLETED · PHASE3
• Eosinophilia Diagnosis — COMPLETED · NA
• Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment — NOT_YET_RECRUITING · PHASE3
• Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome — ACTIVE_NOT_RECRUITING · PHASE2
• Identification of New Markers in the Hypereosinophilic Syndrome — COMPLETED · NA
• Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) — COMPLETED · PHASE2
• A Phase 3, 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome. — OTHER · PHASE3
• This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic — TERMINATED
• Eosinophil Subpopulations in Eosinophilic-associated Diseases — NOT_YET_RECRUITING
• Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome. — OTHER · PHASE3
• TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause — COMPLETED
• Steroid Treatment for Hypereosinophilic Syndrome — COMPLETED · PHASE4
• Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate — COMPLETED · NA
• MAP to Provide Access to Nilotinib, for Patients With HES — TERMINATED
• A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies — COMPLETED · PHASE1
• Phase II Gleevec Idiopathic Hypereosinophilic Syndrome — TERMINATED · PHASE2
• A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 — COMPLETED · PHASE3
• Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) — COMPLETED · PHASE3
• Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) — COMPLETED · PHASE3
• Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome — OTHER · PHASE2
• Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome — TERMINATED · PHASE3
• Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes — COMPLETED · PHASE2
• A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome — TERMINATED · PHASE2
• Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes — COMPLETED · PHASE2
• Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias — OTHER · PHASE2
• Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome — COMPLETED · PHASE2

Refine this search